ArticleCureus2026
Intraoperative Mitigation Strategies Aimed at Reducing Clinically Relevant Postoperative Pancreatic Fistula After Pancreaticoduodenectomy: A Single-Center Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Clinically relevant postoperative pancreatic fistula (CR-POPF) remains one of the most important drivers of morbidity after pancreaticoduodenectomy (PD). Several intraoperative adjuncts have been proposed to protect the pancreatic anastomosis or reduce ductal and biliopancreatic pressure, but their comparative real-world impact remains uncertain. Methods We conducted a retrospective single-center cohort study of consecutive adult patients who underwent PD at ASST Cremona between December 2021 and January 2026. Patients were stratified according to the 2016 International Study Group of Pancreatic Surgery classification into no POPF, Grade B POPF, and Grade C POPF. The primary endpoint was CR-POPF, defined as Grade B or C POPF. Intraoperative adjuncts of interest included intraoperative percutaneous transhepatic biliary drainage (PTBD), sponge-assisted negative-pressure drainage, coronary stent support of the pancreatic anastomosis, and externalized Wirsung duct stenting. Secondary outcomes included major morbidity (Clavien-Dindo ≥3a), postoperative interventions, reoperation, unplanned ICU admission, length of stay, readmission, and 30-day mortality. Results Seventy-six patients were included. Overall, 52 patients (68.4%) did not develop POPF, while 24 (31.6%) developed CR-POPF, including 18 Grade B fistulas (23.7%) and six Grade C fistulas (7.9%). A soft pancreatic remnant, a smaller main pancreatic duct diameter, and a higher Fistula Risk Score (FRS) were significantly associated with POPF. Intraoperative PTBD was used in 56 patients (73.7%), externalized Wirsung duct stenting in 40 (52.6%), coronary stenting in 35 (46.1%), and sponge-assisted drainage in five (6.6%). In exploratory parsimonious logistic regression models, none of the adjunctive strategies was significantly associated with reduced CR-POPF. Low FRS (1-2) was protective against CR-POPF (OR: 0.19; 95% CI: 0.05-0.66; p = 0.009). CR-POPF was associated with longer postoperative stay, higher major morbidity, more abdominal collections, greater need for interventional radiology or endoscopic treatment, reoperation, unplanned ICU admission, and higher 30-day mortality in Grade C cases. Conclusions In this single-center cohort, CR-POPF after PD was mainly associated with pancreatic texture, duct size, and FRS rather than with any single intraoperative adjunct. These findings support individualized, risk-stratified anastomotic protection and highlight the need for larger prospective studies to clarify which patients may benefit from specific technical adjuncts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.